Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the GSK 401K plan, which is notionally held in GSK American Depositary Shares (ADSs). On July 19, 2013, at a price of $52.15 per ADS, the following increase in notional allocation occurred:
- Dr. M. Slaoui (Director): No change in ADS allocation.
- Dr. K. Slaoui (Connected Person): Increase of 3 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the transaction described above in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction date: July 19, 2013.
- Transaction price: $52.15 per ADS.
- Beneficiary of increase: Dr. K. Slaoui (Connected Person) received 3 additional notional ADSs.
- Plan involved: GSK 401K plan (notional investment in ADSs).
- Reporting date: July 22, 2013.